Media coverage about Urogen Pharma (NASDAQ:URGN) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Urogen Pharma earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.0775973653479 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

A number of equities analysts have recently weighed in on URGN shares. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Jefferies Group LLC upped their target price on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a report on Monday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $28.50.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/13/urogen-pharma-urgn-given-media-sentiment-rating-of-0-08.html.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Insider Buying and Selling by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Stock Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related stocks with our FREE daily email newsletter.